Page last updated: 2024-09-05

lenalidomide and lfm a13

lenalidomide has been researched along with lfm a13 in 1 studies

Compound Research Comparison

Studies (lenalidomide)	Trials (lenalidomide)	Recent Studies (post-2010) (lenalidomide)	Studies (lfm a13)	Trials (lfm a13)	Recent Studies (post-2010) (lfm a13)
3,532	725	2,850	50	0	22

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L	1

Other Studies

1 other study(ies) available for lenalidomide and lfm a13

Article	Year
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cellular signalling, 2013, Volume: 25, Issue:1 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured	2013

Article

Year

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.

Cellular signalling, 2013, Volume: 25, Issue:1

Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured

2013